Effects of Low Dose Sympathetic Inhibition on Glomerulosclerosis and Albuminuria in Subtotally Nephrectomized Rats
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
: A potential role of the sympathetic nervous system in progression of renal failure has received little attention. This study examined whether nonhypotensive doses of moxonidine, an agent that reduces sympathetic activity, affects glomerulosclerosis, urine albumin excretion, and indices of renal handling of norepinephrine (NE) in subtotally nephrectomized (SNX) rats. Sprague Dawley rats were SNX or sham-operated (control). SNX rats were either left untreated or treated with moxonidine in a dose (1.5 mg/kg body wt per d) that did not modify telemetrically monitored 24-h BP. Glomerular and renal morphology were evaluated by quantitative histology, immunohistochemistry, and in situ hybridization. Urine albumin excretion rate was analyzed by enzyme-linked immunosorbent assay, and kidney angiotensin II and NE content were measured using HPLC, 3 H-NE uptake, and release. Body and kidney weight and BP were not significantly different between SNX with or without moxonidine. The glomerulosclerosis index was significantly lower in moxonidine-treated (0.88 ± 0.09) compared with untreated (1.55 ± 0.28) SNX rats, as was the index of vascular damage (0.32 ± 0.14 versus 0.67 ± 0.16). The number of proliferating cell nuclear antigen-positive glomerular and tubular cells per area was significantly higher in untreated SNX rats than in controls and moxonidine-treated SNX rats. The same was true for urine albumin excretion rate. Renal angiotensin II tissue concentration was not affected by moxonidine. In untreated SNX rats, renal nerve stimulation and exogenous NE induced an increase in isolated kidney perfusion pressure (102 ± 21 versus 63 ± 8 mmHg). Renal endogenous NE content was significantly lower in SNX rats than in controls (86 ± 14 versus 140 ± 17 pg/mg wet weight). Cortical uptake of [3 H]-NE was not different, but cortical NE release was significantly higher in SNX rats than in controls. Reduced function of presynaptic inhibitory α-adreno-receptors is unlikely because an α 2-adrenoceptor antagonist increased NE release. At subantihypertensive doses, moxonidine ameliorates renal structural and functional damage in SNX animals, possibly through central inhibition of efferent sympathetic nerve traffic. In kidneys of SNX rats, indirect evidence was found for increased activity of a reduced number of nerve fibers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sympathetic Overactivity in Patients with Chronic Renal Failure
Converse, R. L., Jacobsen, T. N., Toto, R. D., Jost, C. M. T., Cosentino, F., Fouad-Tarazi, F., & Victor, R. G. (1992) · New England Journal of Medicine · doi:10.1056/nejm199212313272704 · Cited by 1,132
Interactions between the melanocortin system and leptin in control of sympathetic nerve traffic
Haynes, W. G., Morgan, D. A., Djalali, A., Sivitz, W. I., & Mark, A. L. (1999) · Hypertension · doi:10.1161/01.hyp.33.1.542 · Cited by 358
Renal Afferent Denervation Prevents Hypertension in Rats With Chronic Renal Failure
Campese, V. M., & Kogosov, E. (1995) · Hypertension · doi:10.1161/01.hyp.25.4.878 · Cited by 356
Campese, V. M., Kogosov, E., & Koss, M. (1995) · American Journal of Kidney Diseases · doi:10.1016/0272-6386(95)90456-5 · Cited by 173
Cited by
The gut microbiota and the brain–gut–kidney axis in hypertension and chronic kidney disease
Yang, T., Richards, E. M., Pepine, C. J., & Raizada, M. K. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0018-2 · Cited by 753
Sympathetic Activation in Chronic Renal Failure
Schlaich, M. P., Socratous, F., Hennebry, S., Eikelis, N., Lambert, E. A., Straznicky, N., Esler, M. D., & Lambert, G. W. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008040402 · Cited by 408
Mahfoud, F., Cremers, B., Janker, J., Link, B., Vonend, O., Ukena, C., Linz, D., Schmieder, R., Rump, L. C., Kindermann, I., et al. (2012) · Hypertension · doi:10.1161/hypertensionaha.112.193870 · Cited by 303
Self-citationSympathetic hyperactivity in chronic kidney disease: Pathogenesis, clinical relevance, and treatment
Neumann, J., Ligtenberg, G., Klein, I. I., Koomans, H. A., & Blankestijn, P. J. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00552.x · Cited by 304
Sympathetic Overactivity in Chronic Kidney Disease: Consequences and Mechanisms
Kaur, J., Young, B., & Fadel, P. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081682 · Cited by 168
Metadata
- Authors
- AMANN, K., RUMP, L. C., SIMONAVICIENE, A., OBERHAUSER, V., WESSELS, S., ORTH, S. R., GROSS, M.-L., KOCH, A., BIELENBERG, G. W., VAN KATS, J. P., EHMKE, H., MALL, G., & RITZ, E.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2000-08
- Volume
- 11
- Issue
- 8
- Pages
- 1469-1478
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2098616191
- Cited by
- 192
- References
- 4
- FWCI
- 8.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of Low Dose Sympathetic Inhibition on Glomerulosclerosis and Albuminuria in Subtotally Nephrectomized Rats. https://app.cochat.ai/papers/10.1681/asn.v1181469
- The paper
- AMANN, K., RUMP, L. C., SIMONAVICIENE, A., OBERHAUSER, V., WESSELS, S., ORTH, S. R., GROSS, M.-L., KOCH, A., BIELENBERG, G. W., VAN KATS, J. P., EHMKE, H., MALL, G., & RITZ, E. (2000). Effects of Low Dose Sympathetic Inhibition on Glomerulosclerosis and Albuminuria in Subtotally Nephrectomized Rats. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.v1181469
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.